EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Projecting the Benefit of Vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA Trial

Veraprapas Kittipibul, Robert J Mentz, Rebecca Young, Javed Butler, Justin A Ezekowitz, Carolyn S P Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M O'Connor, Kevin J Anstrom und 2 weitere

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15134 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Veraprapas Kittipibul und 13 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Pyrimidines, Ventricular Function, Left. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme Corp, Bayer AG, Merck Sharp and Dohme United Kingdom.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high-risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM-HF and DAPA-HF trials.

Methods

Subgroups of VICTORIA participants (n = 5050) were generated to simulate PARADIGM-HF and DAPA-HF trial populations. The PARADIGM-HF-eligible population excluded participants not meeting left ventricular ejection fraction (LVEF), estimated glomerular filtration rate (eGFR), and minimal dose criteria and those with high predicted probability of run-in failure. The DAPA-HF-eligible population excluded those not meeting LVEF and eGFR criteria or with recent (<30 days) HF hospitalization. The time-to-first-event analysis was performed using an unadjusted Cox proportional hazards model.

Results

A total of 1982 (39.2%) and 2543 (50.4%) VICTORIA participants were respectively deemed eligible for PARADIGM-HF and DAPA-HF. Vericiguat was associated with numerically larger reductions in the primary outcome of HF hospitalization or cardiovascular death in populations simulated from PARADIGM-HF [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.72–0.99] and DAPA-HF (HR 0.82, 95% CI 0.71–0.94) compared with the overall VICTORIA trial (HR 0.90). Significant reduction in HF hospitalization with vericiguat was also observed in the DAPA-HF-eligible population (HR 0.83, 95%CI 0.73–0.95) and with a nominal reduction in the PARADIGM-HF-eligible population (HR 0.86, 95% CI 0.74–1.01).

Conclusions

A trend towards enhanced efficacy of vericiguat in populations simulated from PARADIGM-HF and DAPA-HF was observed. These findings support further exploration of vericiguat in lower-risk HF populations as is being investigated in the ongoing VICTOR (a study of vericiguat in participants with chronic heart failure with reduced ejection fraction) trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumePyrimidinesVentricular Function, LeftHumansMaleFemaleMiddle AgedAgedHospitalizationGlomerular Filtration RateFollow-Up StudiesTreatment OutcomeDouble-Blind MethodSurvival RateHeterocyclic Compounds, 2-Ring

Stichwörter der Autor:innen

clinical trialheart failuresoluble guanylate cyclase stimulatorsvericiguat

Substanzen

vericiguatPyrimidinesHeterocyclic Compounds, 2-Ring

Autor:innen und Institutionen

  • Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA.
  • Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
  • Baylor Scott and White Research Institute, Dallas, Texas, USA.
  • Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.
  • National Heart Centre Singapore and Duke-National University of Singapore, Singapore.

Förderung

  • Merck Sharp & Dohme Corp
  • Bayer AG
  • Merck Sharp and Dohme United Kingdom
  • Bayer

Zitieren

APA

Kittipibul, V., Mentz, R. J., Young, R., Butler, J., Ezekowitz, J. A., Lam, C. S. P., Ponikowski, P., Voors, A., Corda, S., McMullan, C., O'Connor, C. M., Anstrom, K. J., Armstrong, P. W., & VICTORIA Study Group (2025). Projecting the Benefit of Vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA Trial. ESC Heart Failure. https://doi.org/10.1002/ehf2.15134

Vancouver

Kittipibul V, Mentz RJ, Young R, Butler J, Ezekowitz JA, Lam CSP, et al. Projecting the Benefit of Vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA Trial. ESC Heart Failure. 2025. doi:10.1002/ehf2.15134

BibTeX
@article{Kittipibul2025,
  author = {Kittipibul, Veraprapas and Mentz, Robert J and Young, Rebecca and Butler, Javed and Ezekowitz, Justin A and Lam, Carolyn S P and Ponikowski, Piotr and Voors, Adriaan and Corda, Stefano and McMullan, Ciaran and O'Connor, Christopher M and Anstrom, Kevin J and Armstrong, Paul W and VICTORIA Study Group, VICTORIA Study Group},
  title = {Projecting the Benefit of Vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA Trial},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15134}
}
Kostenlos starten →